Samuel D. Riccitelli, President & CEO Of Signal Genetics, Talks This Year's IPO, MyPRS And Multiple Myeloma

SecretCaps' recorded a compelling interview With Samuel D. Riccitelli, President and CEO of Signal Genetics SGNL.

Topics covered in this interview include:

Signal Genetics' President and CEO Samuel D. Riccitelli

• Who is Signal Genetics, and what do they do?
• What is multiple Myeloma, and what are the current detection options.
• Why Signal Genetics' MyPRS system not only helps patients, but doctors - like never before.
• The target market available for MyPRS, and SGNL's current market penetration.
• The alpha for Signal Genetics - the ability for growth hinged on testing, not a binary drug approval scenario.
• SGNL's growth potential within teaching universities.
• SGNL's differentiation from other companies in the space - no need for FDA approvals and packing a growing revenue base.
• Valuable insight into this nanocap company that has gone undiscovered in the marketplace.
• Signal Genetics has flown under the radar since its IPO this past summer. This interview is intended to provide valuable insight on an undiscovered nano-cap company.

Access The Full Interview Here

Join SecretCaps for unmatched Microcap research, full access to our recorded CEO interview library and real-time trade alerts.

Members have access first to undiscovered microcap companies prior to institutional investors finding and investing in them.

By viewing this post you agree to SecretCaps' full disclosure.